Not only is the XBI continuing to hover around a historic high, but drug companies can’t seem to get enough of both large IPOs and big-ticket M&A.
An article from
Not only is the XBI continuing to hover around a historic high, but drug companies can’t seem to get enough of both large IPOs and big-ticket M&A.
Published Aug. 28, 2026
An image of a glass flask in a laboratory with stock market information in the background.
Getty Images
Large-cap drug makers appear willing to absorb years of dilution today in exchange for growth tomorrow.
The biotech stock rally that began in April 2025 has not stopped, and if anything, has accelerated.
In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in…
Biotech is dominating the (very) early 2026 deals market.
Biotech firms are gaining major traction in 2026 due to the global pandemic. Take a look at some of the key features of biotech…
XBI saw gains while the major indexes showed a rotation out of the AI leaders.
